Guidant (NYSE:GDT)
Historical Stock Chart
From Feb 2020 to Feb 2025
![Click Here for more Guidant Charts. Click Here for more Guidant Charts.](/p.php?pid=staticchart&s=NY%5EGDT&p=8&t=15)
Guidant Corporation (NYSE:GDT) today announced that the
company has launched the RX HERCULINK(R) ELITE(TM) Biliary Stent
System in the United States, following U.S. Food and Drug
Administration (FDA) 510(k) clearance. The company also received
Conformite Europeene (CE) Mark approval, and has begun marketing the
stent system in the European Union.
The RX HERCULINK ELITE Biliary Stent System is the industry's
first .014 rapid-exchange biliary stent system using cobalt chromium,
a material that is stronger and more radiopaque than stainless steel.
This new stent system improves on Guidant's previous generation of
.014 biliary stents by increasing flexibility and radial strength, and
making the stent more visible and deliverable.
"With RX HERCULINK's legacy of proven deliverability and the
advantages of cobalt chromium, the RX HERCULINK ELITE Biliary Stent
System is the next generation of biliary stenting technology," said
Ron Lattanze, president, Endovascular Solutions, Guidant Corporation.
"Guidant remains focused on providing innovative products to
physicians and their patients."
Guidant introduced the RX HERCULINK Biliary Stent System, the
first .014 biliary system, in 1999, and the enhanced RX HERCULINK(R)
PLUS Biliary Stent System in 2001. In the United States, the RX
HERCULINK PLUS Biliary Stent System and RX HERCULINK ELITE Biliary
Stent System are indicated for the treatment of malignant biliary
obstructions, blockages found in the ducts that carry fluids from the
liver to the gallbladder or from the gallbladder to the small
intestine. These obstructions affect more than 30,000 patients in the
United States each year.
Guidant Corporation pioneers lifesaving technology, giving an
opportunity for better life today to millions of cardiac and vascular
patients worldwide. The company, driven by a strong entrepreneurial
culture of 12,000 employees, develops, manufactures and markets a
broad array of products and services that enable less invasive care
for some of life's most threatening medical conditions. For more
information visit www.guidant.com.
NOTE TO MEDIA: For more information about Guidant, including its
products and services, please visit the company's newsroom at
www.guidant.com/newsroom.